

# Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco

Gabriel Chamie,<sup>1,a</sup> Carina Marquez,<sup>1,a</sup> Emily Crawford,<sup>1,2,b</sup> James Peng,<sup>1</sup> Maya Petersen,<sup>3</sup> Daniel Schwab,<sup>4</sup> Joshua Schwab,<sup>3</sup> Jackie Martinez,<sup>1</sup> Diane Jones,<sup>5</sup> Douglas Black,<sup>1</sup> Monica Gandhi,<sup>1</sup> Andrew D. Kerkhoff,<sup>1</sup> Vivek Jain,<sup>1</sup> Francesco Sergi,<sup>1</sup> Jon Jacobo,<sup>6</sup> Susana Rojas,<sup>6</sup> Valerie Tulier-Laiwa,<sup>6</sup> Tracy Gallardo-Brown,<sup>6</sup> Ayesha Appa,<sup>1</sup> Charles Chiu,<sup>1</sup> Mary Rodgers,<sup>7</sup> John Hackett Jr,<sup>7</sup> CLIAhub Consortium,<sup>2,b</sup> Amy Kistler,<sup>2,b</sup> Samantha Hao,<sup>2,b</sup> Jack Kamm,<sup>2,b</sup> David Dwyer,<sup>2,b</sup> Joshua Batson,<sup>2,b</sup> Bryan Greenhouse,<sup>1</sup> Joe DeRisi,<sup>1,2,b</sup> and Diane V. Havlir<sup>1</sup>

<sup>1</sup>University of California, San Francisco, San Francisco, California, USA, <sup>2</sup>Chan Zuckerberg Biohub, San Francisco, California, USA, <sup>3</sup>University of California, Berkeley, Berkeley, California, USA, <sup>4</sup>College of the Holy Cross, Worcester, Massachusetts, USA, <sup>5</sup>Unidos en Salud/United in Health, San Francisco, California, USA, <sup>6</sup>Latino Task Force for COVID-19, San Francisco, California, USA, and <sup>7</sup>Abbott Laboratories, Abbott Park, Illinois, USA

**Background.** There is an urgent need to understand the dynamics and risk factors driving ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission during shelter-in-place mandates.

**Methods.** We offered SARS-CoV-2 reverse-transcription polymerase chain reaction (PCR) and antibody (Abbott ARCHITECT IgG) testing, regardless of symptoms, to all residents (aged  $\geq 4$  years) and workers in a San Francisco census tract (population: 5174) at outdoor, community-mobilized events over 4 days. We estimated SARS-CoV-2 point prevalence (PCR positive) and cumulative incidence (antibody or PCR positive) in the census tract and evaluated risk factors for recent (PCR positive/antibody negative) vs prior infection (antibody positive/PCR negative). SARS-CoV-2 genome recovery and phylogenetics were used to measure viral strain diversity, establish viral lineages present, and estimate number of introductions.

**Results.** We tested 3953 persons (40% Latinx; 41% White; 9% Asian/Pacific Islander; and 2% Black). Overall, 2.1% (83/3871) tested PCR positive: 95% were Latinx and 52% were asymptomatic when tested; 1.7% of census tract residents and 6.0% of workers (non-census tract residents) were PCR positive. Among 2598 tract residents, estimated point prevalence of PCR positives was 2.3% (95% confidence interval [CI], 1.2%–3.8%); 3.9% (95% CI, 2.0%–6.4%) among Latinx persons vs 0.2% (95% CI, .0%–.4%) among non-Latinx persons. Estimated cumulative incidence among residents was 6.1% (95% CI, 4.0%–8.6%). Prior infections were 67% Latinx, 16% White, and 17% other ethnicities. Among recent infections, 96% were Latinx. Risk factors for recent infection were Latinx ethnicity, inability to shelter in place and maintain income, frontline service work, unemployment, and household income  $< \$50\,000$ /year. Five SARS-CoV-2 phylogenetic lineages were detected.

**Conclusions.** SARS-CoV-2 infections from diverse lineages continued circulating among low-income, Latinx persons unable to work from home and maintain income during San Francisco's shelter-in-place ordinance.

**Keywords.** community-based SARS-CoV-2 testing; asymptomatic SARS-CoV-2 infection; shelter-in-place; ethnic disparities; phylogenetic analysis.

In early 2020, multiple introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the United States (US) laid the foundation for the ongoing epidemic that has claimed  $>100\,000$  US lives in  $<6$  months [1]. Some of the

earliest clinical cases of coronavirus disease 2019 (COVID-19) were recognized in California [2], and the state led the nation in issuing a statewide shelter-in-place mandate on 19 March 2020 [3]. San Francisco declared a local emergency on 25 February 2020 and issued a series of increasingly restrictive mandates on sizes of gatherings, culminating in a shelter-in-place order on 16 March 2020. Although peak hospitalization and death rates in San Francisco over the ensuing month were nearly 10-fold lower than hard-hit cities such as New York [4], the pattern of disproportionately higher hospitalizations among Latinx (persons of Latin American origin or descent) communities was similar [5]. In San Francisco, 45% of reported COVID-19 cases are among Latinx people, who represent 15% of the city's population, and at San Francisco General Hospital, a large public

Received 14 July 2020; editorial decision 11 August 2020; accepted 17 August 2020; published online August 21, 2020.

<sup>a</sup>G. C. and C. M. contributed equally to this work.

<sup>b</sup>CLIAhub Consortium contributed to this work.

Correspondence: G. Chamie, Division of HIV, Infectious Diseases and Global Medicine, San Francisco/San Francisco General Hospital, Box 0874, 995 Potrero Ave, San Francisco, CA 94110 (gabriel.chamie@ucsf.edu).

Clinical Infectious Diseases® 2021;73(S2):S127–35

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/ciaa1234

hospital with a patient population that is 31% Latinx, 81% of COVID-19-related hospitalizations from March to May 2020 were among Latinx people [6, 7].

Hospitalizations and deaths represent a small fraction of total SARS-CoV-2 infections [8–10]. Estimates of the burden of community SARS-CoV-2 infections from direct measurements have been difficult to obtain and compare because symptomatic testing programs capture only a proportion of cases [11], the recognized symptoms associated with COVID-19 have expanded over time [12], the assays used to identify infection have variable performance characteristics, and easily accessible testing programs are not in place for some of the most highly affected communities. Data on community transmission and ethnic disparities in SARS-CoV-2 infection, as opposed to COVID-19 disease [13], as well as systematic efforts to determine factors driving these disparities, remain limited [14].

To estimate the point prevalence and cumulative incidence of infection, determine risk factors for ongoing vs prior infection, and characterize ongoing transmission and viral strain diversity with phylogenetic analyses, we offered population-based, universal polymerase chain reaction (PCR) and antibody testing for SARS-CoV-2 infection, regardless of symptoms, to all residents of a densely populated census tract within a majority Latinx community in San Francisco.

## METHODS

Unidos en Salud (United in Health) is a longitudinal study to characterize SARS-CoV-2 epidemiology and assess impact of public health measures within a US census tract in San Francisco. Six weeks into the city's shelter-in-place ordinance, we provided cross-sectional, mass, low-barrier SARS-CoV-2 reverse-transcription PCR (RT-PCR) and antibody testing, regardless of symptoms, to residents (aged  $\geq 4$  years) and people who work but may not reside in the census tract.

### Study Setting and Community Mobilization

The US census tract 022901 is a population-dense, 16-square-block (0.1 square mile) area in San Francisco's Mission District, with 5174 residents, of whom 58% are Latinx, 34% White, 5% Asian/Pacific Islander, and 1% Black/African American. Median per capita income was \$40 420/year in 2018, with 34% of households earning  $< \$50\ 000$ /year and 20% earning  $> \$200\ 000$ /year [15]. In partnership with the Latino Task Force for COVID-19, an umbrella organization coordinating local Latinx community-based organizations, we distributed flyers, mobilized the community on local and social media, and offered online and door-to-door preregistration within the census tract for testing appointments during the week prior to the testing campaign.

### Testing Campaign

From 25–28 April 2020, we offered outdoor testing at public parks and schools to those who provided an address in the

census tract or worked in the tract. On 28 April, we expanded eligibility to residents of neighboring city blocks (2 blocks north, 3 blocks east, and 1 block south), responding to high community demand. During preregistration, we conducted a brief survey. At the time of testing, we obtained verbal consent for participation and conducted COVID-19 symptom screening. Medical staff performed a fingerstick blood collection (500  $\mu\text{L}$ ) for antibody testing and an oropharyngeal/midturbinates nasal swab for quantitative RT-PCR. Participants could opt out of either test. We contacted all PCR-positive persons to disclose results and perform a clinical assessment. We provided household support via a community-led team for PCR-positive participants and evaluated symptoms among all PCR-positive participants over 2 weeks following testing.

### Laboratory Assays

Swabs were collected in DNA/RNA Shield (Zymo Research) to inactivate virus and preserve RNA stability. RT-PCR of viral N and E genes and human RNase P gene was performed on extracted RNA at a Clinical Laboratory Improvement Amendments–certified laboratory operated by the University of California, San Francisco and the Chan Zuckerberg Biohub using a laboratory-developed test with a limit of detection of  $\log_{10}$  4.5 viral genome copies/mL. SARS-CoV-2–positive RNA samples were subjected to Primal-Seq Nextera XT version 2.0 [16], using the ARTIC Network V3 primers [17], followed by paired-end  $2 \times 150$ -bp sequencing on an Illumina NovaSeq platform. For antibody testing, the ARCHITECT SARS-CoV-2 IgG Emergency Use Authorization (EUA) assay (Abbott Laboratories, Abbott Park, Illinois) [18] was performed on participants' plasma from the fingerstick collections, which is a research use of the test.

### Study Outcomes

Outcomes included the estimated point prevalence of all PCR-positive infections, recent infections (PCR positive and antibody negative), and prior infections (antibody positive and PCR negative). Cumulative incidence of infection was defined as any PCR- or antibody-positive result. Phylogenetics was used to measure strain diversity.

### Statistical Analyses

Proportions were compared using  $\chi^2$  test and medians were compared using Wilcoxon rank-sum test. Cumulative incidence of infection was adjusted for RT-PCR and antibody test characteristics; 95% confidence intervals (CIs) incorporating uncertainty in test characteristics were based on bootstrap. For census tract residents, we further adjusted for differences in age, sex, and race/ethnicity of participants compared to 2018 census estimates (Supplementary Methods). We used multivariate logistic regression for the dependent outcome of PCR positivity among participants tested and included the independent

variables sex, frontline worker status, household income, and reporting a COVID-19 contact, based on a priori interest and univariate results. We did not adjust CIs for multiple testing.

### Bioinformatics and Genomic Analyses

A phylogenetic tree was constructed containing all 123 SARS-CoV-2 genomes from San Francisco County on GISAID [19] on 22 May 2020 together with the high-quality consensus genomes assembled from this study, using the Nextstrain toolkit [20]. Global clade identification and naming follows the Nextstrain proposal [21], and significance of population structure computed by a permutation test was used for Hudson fixation index (FST) (Supplementary Methods) [22].

### Ethics Statement

The UCSF Committee on Human Research determined that the study met criteria for public health surveillance.

## RESULTS

### Testing Uptake and Coverage

Overall, 3953 persons were tested during the campaign. Of all persons tested, 53% were male, and 40% identified as Latinx, 41% White, 9% Asian/Pacific Islander, 2% Black, and 7% other/mixed ethnicity (Table 1). A significantly higher proportion of Latinx compared to non-Latinx participants reported annual household income <\$50 000/year (62% vs 19%), living with >5 persons/household (25% vs 5%) and working frontline service jobs (43% vs 17%; Supplementary Table 1). Estimated census tract testing coverage of adult residents (aged ≥20 years) was 60%.

### SARS-CoV-2 Infection by PCR Testing

Among 3871 tested by SARS-CoV-2 RT-PCR, 2.1% (83 people) tested PCR positive: 1.7% (43/2598; 95% CI, 1.2%–2.2%) of census tract residents, 6.0% (27/450; 95% CI, 4.0%–8.6%) of tract workers, and 1.6% (13/823; 95% CI, .8%–2.7%) of residents of neighboring city blocks. Among all persons tested, 237 (6.1%) reported symptoms compatible with COVID-19, of whom 31 (13.1%) tested PCR positive. Twelve people (0.3% of all persons tested) reported having had a prior positive test for COVID-19, of whom 5 tested PCR positive.

Among PCR-positive persons, 95% identified as Latinx, the median age was 38 years (interquartile range [IQR], 28–50 years), and 76% were male. Persons testing PCR positive were significantly more likely than persons testing PCR negative to identify as Latinx, report inability to shelter-in-place and maintain income, work frontline-service jobs or be unemployed, and live in households with income <\$50 000/year and ≥3 persons/household (Table 2). Given that 95% of PCR-positive persons were Latinx, we limited our multivariate model to Latinx participants to evaluate risk factors for PCR positivity within this group, and found significantly higher odds

of PCR-positive infection if male (odds ratio [OR], 2.0 [95% CI, 1.1–3.6];  $P = .02$ ), working a frontline service job (OR, 2.6 [95% CI, 1.4–5.1];  $P = .004$ ; reference: nonfrontline), household income <\$50 000/year (OR, 8.9 [95% CI, 1.9–158];  $P = .03$ ; reference: >\$100 000/year), or reporting a COVID-19 contact (OR, 3.6 [95% CI, 2.0–6.3];  $P < .001$ ).

Estimated point prevalence of PCR-positive infection in the census tract after adjusting for age and sex of participants in the testing campaign vs census demographics was 2.3% (95% CI, 1.2%–3.8%): 3.9% (95% CI, 2.0%–6.4%) among Latinx vs 0.2% (95% CI, .0%–.4%) among non-Latinx tract residents. Among Latinx people who worked in the census tract, unadjusted point prevalence of PCR-positive infection was 10.4% (95% CI, 7.0%–14.8%), compared to 0.0% (95% CI, .0%–2.0%) among non-Latinx workers.

### Clinical Characteristics of PCR-Positive Persons

Among 83 PCR-positive persons, 43 (52%) were asymptomatic at the time of testing. Two-week follow-up was obtained for 41 participants who were asymptomatic at the time of testing: 8 of 41 (20%) recalled mild symptoms that had resolved by the time of testing, 10 (24%) developed symptoms after testing (presymptomatic) and 23 (56%) remained asymptomatic. Based on reclassified symptom status among PCR-positive people, 39 of 80 (49%) were symptomatic at time of testing, 8 (10%) were previously symptomatic, 10 (12.5%) were presymptomatic, and 23 (29%) remained asymptomatic throughout infection. One PCR-positive person (1.3%) required hospitalization.

### SARS-CoV-2 Cumulative Incidence and Recent Versus Prior Infections

Among 3861 participants tested for SARS-CoV-2 antibodies, 3.4% (131) tested antibody positive: 3.1% (80/2545; 95% CI, 2.5%–3.9%) among census tract residents compared to 7.7% (34/442; 95% CI, 5.4%–10.6%) among tract workers and 2.1% (17/829; 95% CI, 1.2%–3.3%) among adjacent city block residents. Estimated cumulative incidence (antibody or PCR-positive) among tract residents was 4.4% (95% CI, 3.2%–5.6%) after adjusting for test characteristics and 6.1% (95% CI, 4.0%–8.6%) after further adjusting for participation (Supplementary Table 2).

Among all infections detected by PCR or antibody, 26% (48/182) were recent infection, and 53% (96/182) were prior infection. Of the remaining infections, 18% (32/182) were PCR positive/antibody positive, and 3% (6/182) had PCR or antibody testing alone (Supplementary Table 3). Whereas prior infections occurred across a range of ethnic groups, employment types, and household income levels, recent infections were predominantly among persons who identified as Latinx, worked frontline service jobs, and lived in households with an income <\$50 000/year (Figure 1). Compared to individuals with prior infection, people with recent infection were significantly more likely to be of Latinx ethnicity (OR, 10.1 [95% CI, 2.81–64.6];

**Table 1. Characteristics of Persons Participating in a Population-based Severe Acute Respiratory Syndrome Coronavirus 2 Testing Campaign in the Study Census Tract (United States Census Tract 022901)**

Characteristic	Residents (n = 2653)	Workers <sup>a</sup> (n = 460)	Adjacent City Block Residents (n = 840)	Total (N = 3953)
<b>Sex at birth<sup>b</sup></b>				
Male	1236 (53)	284 (62)	418 (51)	1938 (53)
Female	1118 (47)	173 (38)	408 (49)	1699 (47)
<b>Age category, y</b>				
4–10	78 (3)	12 (3)	28 (3)	118 (3)
11–17	100 (4)	18 (4)	23 (3)	141 (4)
18–50	1695 (64)	278 (60)	559 (67)	2532 (64)
51–70	633 (24)	133 (29)	185 (22)	951 (24)
>70	147 (6)	19 (4)	45 (5)	211 (5)
<b>Race/ethnicity<sup>b</sup></b>				
White	925 (40)	112 (25)	433 (53)	1470 (41)
Hispanic/Latinx	934 (40)	265 (59)	251 (31)	1450 (40)
Black/African American	59 (3)	15 (3)	11 (1)	85 (2)
Asian/Pacific Islander	239 (10)	38 (8)	55 (7)	332 (9)
Other	166 (7)	22 (5)	64 (8)	252 (7)
<b>Occupation<sup>b</sup></b>				
<b>Frontline service jobs</b>				
Food/beverage	176 (8)	125 (28)	70 (9)	371 (11)
Healthcare	128 (6)	21 (5)	43 (5)	192 (5)
Tradesperson (eg, construction, plumbing), cleaning (eg, janitor, housekeeper), or personal services (eg, hairdresser)	244 (11)	76 (17)	75 (9)	395 (11)
<b>Non-frontline service jobs</b>				
Education	119 (5)	13 (3)	53 (6)	185 (5)
Finance, sales, and technology	486 (21)	31 (7)	155 (19)	672 (19)
Student	191 (8)	34 (8)	71 (9)	296 (8)
Retired/homemaker	219 (10)	23 (5)	76 (9)	318 (9)
Unemployed	160 (7)	27 (6)	50 (6)	237 (7)
Other occupation	542 (24)	91 (21)	230 (28)	863 (24)
<b>Household information<sup>b</sup></b>				
<b>No. of people per HH</b>				
1–2	807 (36)	125 (31)	338 (41)	1270 (37)
3–5	1092 (49)	212 (53)	417 (51)	1721 (50)
>5	313 (14)	66 (16)	68 (8)	447 (13)
<b>Rooms/HH</b>				
1–2	684 (32)	154 (39)	260 (32)	1098 (33)
3–4	898 (42)	174 (44)	338 (42)	1410 (43)
>4	535 (25)	64 (16)	208 (26)	807 (24)
<b>Annual income per HH</b>				
<\$50 000/y	819 (36)	253 (58)	205 (25)	1277 (36)
\$50 000–100 000/y	604 (27)	105 (24)	202 (25)	911 (26)
>\$100 000/y	831 (37)	78 (18)	407 (50)	1316 (38)
Homeless	43 (2)	12 (3)	5 (1)	60 (2)
<b>Past medical history<sup>b</sup></b>				
Chronic lung disease	287 (12)	54 (12)	113 (14)	454 (13)
Chronic heart disease	120 (5)	24 (5)	35 (4)	179 (5)
Hypertension	325 (14)	76 (17)	81 (10)	482 (13)
Diabetes	148 (6)	32 (7)	33 (4)	213 (6)
Smoker <sup>c</sup>	540 (23)	103 (23)	174 (21)	817 (23)
<b>COVID-19–related history</b>				
Reported prior positive test for COVID-19	5 (0.2)	1 (0.2)	6 (0.7)	12 (0.3)
Reported having a personal contact diagnosed with COVID-19	175 (8)	72 (16)	69 (8)	316 (9)
Reported being able to shelter in place and maintain income	993 (47)	79 (19)	377 (49)	1449 (44)

Data are presented as no. (%).

Abbreviations: COVID-19, coronavirus disease 2019; HH, household Latinx, persons of Latin American origin or descent.

<sup>a</sup>Includes workers and family members of people who reported working in the census tract.<sup>b</sup>Excludes testing campaign participants with missing responses (ie, not provided) during the testing survey.<sup>c</sup>Tobacco or marijuana.

$P = .002$ ; reference: non-Latinx ethnicity), report inability to shelter-in-place and maintain income (OR, 3.18 [95% CI, 1.10–11.6];  $P = .048$ ), work frontline service jobs (OR, 2.83 [95% CI, 1.21–6.93];  $P = .019$ ), or be unemployed (OR, 3.47 [95% CI, 1.08–11.3];  $P = .035$ ; reference: nonfrontline service jobs), and live in households with income  $< \$50\,000$ /year (OR, 19.3 [95% CI, 3.74–356];  $P = .005$ ; reference: household income  $> \$100\,000$ /year) (Supplementary Table 4).

### SARS-CoV-2 RNA Levels and Phylogenetic Analysis

Median levels of virus as estimated by RT-PCR cycle thresholds were significantly higher among PCR-positive/antibody-negative persons compared to PCR-positive/antibody-positive persons, supporting our classification of recent infection (Figure 2). Among recently infected individuals, median levels

of virus by RT-PCR cycle threshold did not differ significantly between symptomatic (24 [IQR, 19–25]; range, 11–35;  $n = 27$ ) and asymptomatic (24 [IQR, 19–26]; range, 16–32;  $n = 10$ ;  $P = .98$ ) persons (Figure 2); additional comparisons by subgroup are shown in Supplementary Figure 1.

We recovered SARS-CoV-2 genomes from 59% (49/83) of the PCR-positive RNA samples. The recovered genomes were diverse and phylogenetically intermixed with samples from across San Francisco, including representatives from 5 globally circulating clades, showing multiple independent introductions (Figure 3A). Overall, 58% of PCR-positive participants shared a home with another PCR-positive participant identified in the testing campaign; sequences from such households were consistent with within-household transmission (Figure 3B), with no variants detected in 11 of 17 (65% [95% CI, 41%–83%]) of household links. We found no significant population structure

**Table 2. Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 Testing Campaign Participants Who Tested Polymerase Chain Reaction (PCR) Positive Compared to PCR Negative, and Factors Associated With Increased Odds of PCR Positivity**

Characteristic	PCR Positive (n = 83)	PCR Negative (n = 3788)	Univariate Risk of PCR Positivity, OR (95% CI)	P Value
<b>Sex at birth<sup>a</sup></b>				
Female	20 (24)	1638 (47)	Ref	
Male	63 (76)	1845 (53)	2.71 (1.64–4.69)	<.001
<b>Age category, y</b>				
4–10	4 (5)	104 (3)	Ref	
11–17	2 (2)	127 (3)	0.41 (.06–2.14)	.3
18–50	60 (72)	2429 (64)	0.64 (.26–2.15)	.4
51–70	14 (17)	923 (24)	0.39 (.14–1.41)	.11
>70	3 (4)	205 (5)	0.38 (.07–1.76)	.2
<b>Race/ethnicity<sup>a</sup></b>				
			Ref: non-Hispanic/Latinx	
White	1 (1)	1441 (42)	...	
Hispanic/Latinx	79 (95)	1348 (39)	28.3 (11.7–93.1)	<.001
Asian/Pacific Islander	2 (2)	324 (9)	...	
Other	1 (1)	326 (9)	...	
<b>Occupation<sup>a</sup></b>				
Frontline service job	47 (64)	902 (27)	6.56 (3.86–11.6)	<.001
Non-frontline service job	18 (24)	2267 (67)	Ref	
Unemployed	9 (12)	220 (6)	5.15 (2.18–11.3)	<.001
<b>No. of people per household<sup>a</sup></b>				
1–2	10 (14)	1235 (37)	Ref	
3–5	41 (58)	1645 (50)	3.08 (1.60–6.53)	.002
>5	20 (28)	420 (13)	5.88 (2.79–13.2)	<.001
<b>Annual household income<sup>a</sup></b>				
>\$100 000	2 (3)	1287 (38)	Ref	
\$50 000–\$100 000	7 (9)	889 (26)	5.07 (1.22–34.1)	.043
<\$50 000	65 (88)	1182 (35)	35.4 (11.1–216)	<.001
<b>Past medical history<sup>a</sup></b>				
Any underlying conditions	22 (29)	971 (28)	1.02 (.61–1.66)	.94
<b>COVID-19–related history<sup>a</sup></b>				
No contacts with COVID-19	...	...	Ref	
Personal contact diagnosed with COVID-19	25 (32)	286 (8)	5.29 (3.19–8.57)	<.001
<b>Able to shelter in place and maintain income</b>				
Yes	5 (7)	1417 (45)	Ref	<.001
No	64 (93)	1756 (55)	10.3 (4.58–29.6)	

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; Latinx, persons of Latin American origin or descent; OR, odds ratio; PCR, polymerase chain reaction.

<sup>a</sup>Excludes testing campaign participants with missing responses (ie, not provided) during the testing survey.



separating the Mission District samples from the rest of San Francisco ( $P = .19$ ).

## DISCUSSION


We found stark ethnic and economic disparities in who is at risk for ongoing infection 6 weeks into San Francisco's shelter-in-place ordinance. The estimated point prevalence of PCR-positive infection among Latinx residents (3.9%) was 20 times that of non-Latinx residents (0.2%). Perhaps even more striking was that recent infections were concentrated almost exclusively among low-income, Latinx people working frontline jobs, whereas prior infections occurred among more ethnically and economically diverse individuals. In addition, the majority of PCR-positive infections were asymptomatic at the time of testing, and recently infected individuals had high levels of virus regardless of symptoms. These data show that San Francisco's COVID-19 epidemic has continuing transmission in subgroups of the city population that require urgent attention.

Heterogeneity among populations most affected by the COVID-19 epidemic exists across the US, within states and cities, and even within neighborhoods as shown here. Population-level epidemiologic data coupled with phylogenetic analyses can help identify, track, and inform testing strategies, public health policies, and measures to mitigate health and economic effects. Low-barrier, community-mobilized testing is foundational to these efforts. We sought to overcome some of the testing barriers in this census tract through our partnership with the community-led Latino Task Force in San Francisco, which provided explanations about COVID-19 and communicated the importance of testing to the community. Through this approach, we were able to test a large proportion of the population in a short period of time.

To date, there are limited published data on population-level PCR testing in the US. Our estimated point prevalence of PCR-positive infection among residents (2.3%) was higher than an estimate (1.74%) from a statewide random population sample of persons aged  $\geq 12$  years in Indiana also obtained in late April 2020 [23], and notably higher than that of a community-wide testing study in the coastal town Bolinas, in the San Francisco Bay Area, in which no PCR-positive cases were identified [24].

We determined that during the shelter-in-place order, COVID-19 transmission became increasingly concentrated in Latinx community members. The risk factors driving recent transmission among Latinx residents in our study were largely economic and highly correlated: low-income residents working frontline jobs who could not shelter in place and maintain their income. Unemployed residents may have experienced increased risk of PCR-positive infection as a consequence of seeking employment, particularly among day laborers. Given the evidence of within household transmission, confirmed by SARS-CoV-2 sequencing, we suspect that transmission was amplified in Latinx multigenerational and multifamily households—a byproduct of skyrocketing rental costs in the city [25]. These economic drivers and ethnic disparities observed at the community level here are reflected in COVID-19 hospitalizations and deaths widely reported in the US, in many settings disproportionately affecting Black/African American people [13, 26, 27].

We observed high sequence diversity of SARS-CoV-2 infections in the census tract, similar to the diversity seen in San Francisco more broadly, suggestive of multiple independent introductions over time. Our data suggest that most recent infections during shelter-in-place are due to acquisition of virus when working in the census tract, with subsequent within-home transmission in high-density, low-income households.



**Figure 1.** Characteristics of prior (polymerase chain reaction [PCR] negative and antibody [Ab] positive) vs recent (PCR positive, Ab negative) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among persons participating in a population-based SARS-CoV-2 testing campaign in a densely populated census tract in San Francisco. Abbreviation: Latinx, persons of Latin American origin or descent.


These findings should help dispel common, dangerous pitfalls in interpreting ethnic disparities in infection, such as biological explanations, supposed community behaviors, or stigmatizing communities as transmission “hot spots,” about which others have cautioned [14].

Our results also highlight the importance of SARS-CoV-2 testing in both symptomatic and asymptomatic individuals. Symptom-based testing would have failed to detect >40% of PCR-positive infections in this community, many of whom had high levels of virus. Overall, 29% of PCR-positive infections never developed symptoms, slightly lower than the proportion found (43%) in a population-based SARS-CoV-2 screening study from Iceland [28]. In our study, recently infected people had high levels of virus that did not differ significantly based on symptoms, a finding in line with a recent cohort study from the Republic of Korea [29]. The clear implication of these findings is that testing strategies limited to symptomatic individuals and those seeking testing at health centers alone will fail to limit transmission.


These results have several implications moving forward as shelter-in-place restrictions are lifted. First, more efforts are needed to address uncontrolled epidemics among subpopulations, especially vulnerable populations such as the Latinx community highlighted here. Expanded low-barrier testing—that is, targeted, community-led and mobilized, and not limited to symptomatic persons—is needed. Testing needs to be coupled with social protection of job security and economic support for self-isolation and quarantine (ie, “test and respond”) and culturally responsive contact tracing. Our testing campaign contributed to policy change in San Francisco, with

the mayor announcing on 4 May 2020 that essential workers would be eligible for free SARS-CoV-2 testing regardless of symptoms [30], and then on 28 May 2020 that low-wage workers with COVID-19 would be provided funds to stay home and isolate (“Right to Recover”) [31]. In parallel, longitudinal, population-based cohorts that couple epidemiologic data with PCR and antibody testing and viral sequencing can provide evidence of effectiveness of public health measures and viral introductions over time, enabling evidence-based responses in a dynamic landscape.

Our study has several limitations. SARS-CoV-2 PCR tests do not detect all cases, and antibody sensitivity may be lower in asymptomatic infection, which could have resulted in underestimation of cumulative incidence. False-positive antibody results could result in overestimation of cumulative incidence and misclassification of prior infections. Misclassification of prior infections could also result from infections that occurred, generated antibodies, and resolved to PCR negative over the 6 weeks following the shelter-in-place order. Fingerstick sampling could also impact antibody test performance. However, the EUA antibody test we used has been shown to have a high sensitivity (96.9%–100%) at 17–22 days after symptom onset, and high specificity ( $\geq 99.6\%$ ) with venous drawn plasma [32, 33], and our estimates of cumulative incidence accounted for sensitivity and specificity of the PCR and antibody assays used. Second, selection bias in who chose to test may have affected our estimates. Although we adjusted for demographic differences between participants and community composition based on the 2018 American Community Survey data, these data may not fully reflect tract demographics in 2020. However,



**Figure 2.** Quantitative levels of virus among participants with polymerase chain reaction (PCR)-positive severe acute respiratory syndrome coronavirus 2 infection ( $n = 80$ ) by classification as asymptomatic, presymptomatic, and symptomatic for coronavirus disease 2019 disease as determined over longitudinal follow-up (2 weeks posttesting), and stratified by antibody (Ab) status, with PCR-positive/Ab-negative persons considered consistent with recent infection.



**Figure 3.** Viral genomic diversity among polymerase chain reaction (PCR)-positive participants. *A*, Phylogenetic tree containing Mission District samples (red) and other San Francisco samples (gray). The x-axis marks the number of mutations with respect to the reference genome from Wuhan, China. Yellow arrows mark introductions of 5 major global clades (right brackets) to the study population. *B*, Tree subset to Mission District samples. Shape indicates district resident or worker and color indicates antibody status. Households with multiple PCR-positive persons are drawn in green and include markers for samples from which genomes could not be recovered. Asterisk marks a household outside of the district in which an unhoused person in the district spent time.

population-based testing in a census tract allowed for greater clarity in understanding who did not participate. Last, we relied on self-reported symptoms and survey responses, which may have resulted in misclassification. With follow-up of PCR-positive participants over 2 weeks, we were able to further explore symptom status, allowing for monitoring and reclassification.

In conclusion, improving access to SARS-CoV-2 testing, regardless of symptoms, through community-led, low-barrier testing programs in vulnerable communities is feasible. Adding economic support and protections for low-income workers during isolation and quarantine could further increase testing and contribute to reducing community transmission and the massive disparities in SARS-CoV-2 infection observed in the US.

#### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

#### Notes

**Acknowledgments.** The authors thank the community members from the census tract studied for their generous participation in this study during San Francisco's shelter-in-place ordinance. The authors gratefully acknowledge the contributions of all of the study volunteers who made community-based testing possible, and all the members of the Latino Task Force for COVID-19 who led community mobilization efforts, community outreach and education, and dissemination of these findings to the community. The authors also thank Chesa Cox, MPH, for logistical and administrative support; Stacie Powers for her generous donation of the Brava Theater space to operate as headquarters for the study volunteers and the Community Wellness Team; and San Francisco Recreation and Parks and the San Francisco Unified School District for generously allowing us to offer community-based testing at 2 public parks and 2 public schools. The authors thank Supervisor Hillary Ronen; the San Francisco Mayor's Office; Dr Grant Colfax, Director of the San Francisco Department of Public Health; Elaine Forbes, Executive Director, Port of San Francisco; Naomi Kelly, San Francisco City Administrator; Dr Susan Ehrlich, CEO of Zuckerberg San Francisco General Hospital; and the Ward 86 Clinic staff, for their efforts in support of this community-based testing project. The authors also thank Andrew Kobylinski and Primary Tech for assistance in their virtual support platform and online results reporting, as well as Ana Vallari, Ana Olivo, Barb Harris, and Chris Lark from Abbott Laboratories for helping conduct the antibody assays for this study.

**Disclaimer.** The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.



**Financial support.** This work was supported by the Chan Zuckerberg Biohub; the University of California, San Francisco (UCSF); and a Program for Breakthrough Biomedical Research award. ARCHITECT SARS-CoV-2 test kits were provided by Abbott Laboratories.

**Supplement sponsorship.** This supplement is supported by the Infectious Diseases Society of America through Cooperative Agreement NU50CK000574 with the U.S. Centers for Disease Control and Prevention.

**Potential conflicts of interest.** M. R. and J. H. are employees and shareholders of Abbott Laboratories. C. Y. C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and receives research support funding from Abbott Laboratories. M. G. reports grants from the National Institutes of Health (NIH). V. J. reports grants from the Centers for Disease Control and Prevention and the US President's Emergency Plan for AIDS Relief, outside the submitted work. D. H. and G. C. report grants from the NIH and the Bill & Melinda Gates Foundation, outside the submitted work. J. D. reports grants from Chan Zuckerberg Biohub, outside the submitted work. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Schuchat A; CDC COVID-19 Response Team. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:551–6.
- Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient—Solano County, California, February 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:472–6.
- California State Government. Stay home Q&A. Available at: <https://covid19.ca.gov/stay-home-except-for-essential-needs/>. Accessed 1 June 2020.
- DataSF. COVID-19 data and reports. <https://data.sfgov.org/stories/s/San-Francisco-COVID-19-Data-and-Reports/fjki-2fab/>. Accessed 1 June 2020.
- Wadhwa RK, Wadhwa P, Gaba P, et al. Variation in COVID-19 hospitalizations and deaths across New York city boroughs. *JAMA* 2020; 323:2192–5.
- Palomino J, Sanchez T. Latinos' coronavirus burden. 2020. Available at: <https://www.sfchronicle.com/bayarea/article/Bay-Area-Latinos-hit-hardest-by-coronavirus-15252632.php>. Accessed 4 June 2020.
- DataSF. Population characteristics. Available at: <https://data.sfgov.org/stories/s/w6za-6st8>. Accessed 8 August 2020.
- Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020; 20:669–77.
- Rosenberg ES, Dufort EM, Blog DS, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State—March 2020. *Clin Infect Dis* 2020; 71:1953–9.
- Centers for Disease Control and Prevention. Coronavirus disease: pandemic planning scenarios. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>. Accessed 8 August 2020.
- Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles' heel of current strategies to control Covid-19. *N Engl J Med* 2020; 382:2158–60.
- Centers for Disease Control and Prevention. Coronavirus disease: symptoms. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. Accessed 4 June 2020.
- Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. *N Engl J Med* 2020; 382:2534–43.
- Chowkwanyun M, Reed AL Jr. Racial health disparities and Covid-19—caution and context. *N Engl J Med* 2020; 383:201–3.
- Census Reporter. Census tract 229.01, San Francisco, CA. Available at: <https://censusreporter.org/profiles/14000US06075022901-census-tract-22901-san-francisco-ca/>. Accessed 1 June 2020.
- Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. *Nat Protoc* 2017; 12:1261–76.
- ARTIC Project. hCoV-2019/nCoV-2019 version 3 amplicon set. Available at: <https://artic.network/resources/ncov/ncov-amplicon-v3.pdf>. Accessed 3 June 2020.
- US Food and Drug Administration. SARS-CoV-2 IgG for use with ARCHITECT. Available at: <https://www.fda.gov/media/137383/download>. Accessed 4 June 2020.
- Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAI's innovative contribution to global health. *Glob Chall* 2017; 1:33–46.
- Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in humans. *Bioinformatics* 2015; 31:3546–8.
- Hodcroft EB, Hadfield J, Neher RA, Bedford T. Year-letter genetic clade naming for SARS-CoV-2 on Nextstrain.org. Available at: <https://virological.org/t/year-letter-genetic-clade-naming-for-sars-cov-2-on-nextstrain-org/498>. Accessed 5 June 2020.
- Hudson RR, Slatkin M, Maddison WP. Estimation of levels of gene flow from DNA sequence data. *Genetics* 1992; 132:583–9.
- Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. *Morb Mortal Wkly Rep* 2020; 69:960–4.
- Appa A, Takahashi S, Rodriguez-Barraquer I, et al. Universal SARS-CoV-2 PCR and antibody testing for a rural community. In: International AIDS Society COVID-19 conference, San Francisco, CA, 2020.
- Joint Center for Housing Studies. The state of the nation's housing 2017 (report). Cambridge, MA: Harvard University, Joint Center for Housing Studies, 2017.
- CDC COVID-NET. Characteristics of laboratory-confirmed COVID-19-associated hospitalizations. Available at: [https://gis.cdc.gov/grasp/COVIDNet/COVID19\\_5.html](https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html). Accessed 3 August 2020.
- Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. *JAMA Netw Open* 2020; 3:e2012270.
- Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. *N Engl J Med* 2020; 382:2302–15.
- Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. *JAMA Intern Med* 2020. [Preprint]. August 6, 2020. doi:10.1001/jamainternmed.2020.3862
- NBC Bay Area. San Francisco now offering free COVID-19 testing for all essential workers. Available at: <https://www.nbcbayarea.com/news/local/san-francisco/san-francisco-now-offering-free-covid-19-testing-for-all-essential-workers/2284712/>. Accessed 4 June 2020.
- Fracassa D. SF to pay low-wage workers who get COVID-19 to stay home and isolate. 2020. Available at: <https://www.sfchronicle.com/bayarea/article/SF-rolls-out-new-program-to-help-low-income-15299045.php>. Accessed 4 June 2020.
- Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. *J Clin Microbiol* 2020; 58:e00941-20.
- Ng DL, Goldgof GM, Shy BR, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. medRxiv [Preprint]. May 25, 2020. doi:10.1101/2020.05.19.20107482



Please excuse the presence of this and the following test pages, which have been added to a small number of article PDFs for a limited time as part of our process of continual development and improvement.









Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.